Cargando…

A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly

The 13-valent pneumococcal conjugated vaccine (PCV13) is already recommended for some adult groups and is being considered for wider use in many countries. In order to identify the strengths and limitations of the existing economic evaluation studies of PCV13 in adults and the elderly a literature r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dirmesropian, S, Wood, JG, MacIntyre, CR, Newall, AT
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514194/ https://www.ncbi.nlm.nih.gov/pubmed/25933180 http://dx.doi.org/10.1080/21645515.2015.1011954

Ejemplares similares

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
por: Ansaldi, Filippo, et al.
Publicado: (2020)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
por: Perdrizet, Johnna, et al.
Publicado: (2020)

Estimating the Clinical and Economic Impact of Maintaining use of 13-valent Pneumococcal Conjugate Vaccine (PCV13) in Mexico
por: Wasserman, Matt, et al.
Publicado: (2017)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants
por: Warren, Sophie, et al.
Publicado: (2023)

Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
por: Perdrizet, Johnna, et al.
Publicado: (2021)

Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
por: Dhere, Rajeev, et al.
Publicado: (2022)

Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy
por: Garcia Garrido, Hannah M., et al.
Publicado: (2022)

1441. Doses of 13-Valent Conjugated Pneumococcal Vaccine (PCV13) for Patients With Multiple Myeloma (MM)
por: Sun, Hsin-Yun, et al.
Publicado: (2018)

Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults
por: Atwood, Mark, et al.
Publicado: (2018)

Response to article by Johnna Perdrizet et al.,“Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants”
por: Gómez, Jorge A., et al.
Publicado: (2021)

Population genomics of pneumococcal carriage in South Africa following the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) immunization
por: Javaid, Nida, et al.
Publicado: (2022)

2703. Pneumococcal Carriage of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Non-PCV13 Serotypes among Greek Children Vaccinated with PCV13 in a 3 + 1 Schedule During the First 6 years after the Fourth Dose of PCV13
por: Syrogiannopoulos, George A, et al.
Publicado: (2019)

Direct and Indirect Impact of 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Invasive Pneumococcal Disease (IPD) Among Children and Adults in the U.S.
por: Pilishvili, Tamara, et al.
Publicado: (2017)

Letter to the Editor Regarding: “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
por: Gomez, Jorge A., et al.
Publicado: (2022)

1972. Safety and Immunogenicity of 15-Valent Pneumococcal Conjugate Vaccine (PCV-15) Compared with PCV-13 in Healthy Older Adults Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23)
por: Buchwald, Ulrike, et al.
Publicado: (2018)

1434. Cost-Effectiveness of Sequencial Vaccination With the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23 Valent Polysaccharide Vaccine (PPV23) in The Netherlands
por: Rozenbaum, Mark
Publicado: (2018)

Indirect effect of 7-valent and 13-valent pneumococcal conjugated vaccines on pneumococcal pneumonia hospitalizations in elderly
por: Kislaya, Irina, et al.
Publicado: (2019)

1104 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Immunogenicity in the Community Acquired Pneumonia Immunization Trial In Adults (CAPiTA)
por: Van Deursen, Anna M.M., et al.
Publicado: (2014)

20. Cost-Effectiveness of Implementing 13-Valent Pneumococcal Conjugate Vaccine (Pcv13) for Adults Aged ≥19 Years with Underlying Conditions
por: Kobayashi, Miwako, et al.
Publicado: (2020)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
por: Shiramoto, Masanari, et al.
Publicado: (2015)

2716. Persistence of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Serotypes in Invasive Pneumococcal Disease in Adults in Southern Ontario Canada Despite Routine Pediatric Vaccination
por: McGeer, Allison, et al.
Publicado: (2019)

1474. Impact of 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Non-bacteremic Pneumococcal Pneumonia (NBPP) among Adults in the United States, 2013-2017
por: Gierke, Ryan, et al.
Publicado: (2020)

Decrease of Pneumococcal Community-Acquired Pneumonia Hospitalization and Associated Complications in Children after the Implementation of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Taiwan
por: Shen, Ching-Fen, et al.
Publicado: (2021)

A Response to: Letter to the Editor Regarding “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
por: Perdrizet, Johnna, et al.
Publicado: (2022)

Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children
por: Esposito, Susanna, et al.
Publicado: (2015)

Efficacy and Safety of the Pneumococcal Conjugate-13 Valent Vaccine in Adults
por: Marra, Fawziah, et al.
Publicado: (2019)

P68 - Immunogenicity of 13-valent conjugate pneumococcal vaccine (PCV13) in children with asthma or recurrent wheeze receiving inhaled corticosteroids (ICS)
por: Giannopoulou, Lefki, et al.
Publicado: (2014)

Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States
por: McGarry, Lisa J, et al.
Publicado: (2013)

One-Step Multiplex PCR Assay for Detecting Streptococcus pneumoniae Serogroups/Types Covered by 13-Valent Pneumococcal Conjugate Vaccine (PCV13)
por: Coskun-Ari, Fatma Filiz, et al.
Publicado: (2012)

Immunogenicity and persistence of the 13-valent Pneumococcal Conjugate Vaccine (PCV13) in patients with untreated Smoldering Multiple Myeloma (SMM): A pilot study
por: Bahuaud, Mathilde, et al.
Publicado: (2017)

Pneumonia hospitalisation and case-fatality rates in older Australians with and without risk factors for pneumococcal disease: implications for vaccine policy
por: Dirmesropian, S., et al.
Publicado: (2019)

176. Selected Impact of the 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Invasive Pneumococcal Disease (IPD) at Eight Children’s Hospitals in the United States. 2014–2019
por: Kaplan, Sheldon L, et al.
Publicado: (2020)

Response to Gomez et al.’s Letter to the Editor Regarding: “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
por: Perdrizet, Johnna, et al.
Publicado: (2022)

Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan
por: Hoshi, Shu-ling, et al.
Publicado: (2015)

Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
por: Ghia, Canna J., et al.
Publicado: (2021)

Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis
por: Rozenbaum, Mark H, et al.
Publicado: (2012)

Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia
por: Sundaram, Neisha, et al.
Publicado: (2017)

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
por: Nikolova, Kristiana Alexandrova, et al.
Publicado: (2021)

Correction: One-Step Multiplex PCR Assay for Detecting Streptococcus pneumoniae Serogroups/Types Covered by 13-Valent Pneumococcal Conjugate Vaccine (PCV13)
Publicado: (2015)

Effectiveness of 13-pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease in children in the Dominican Republic
por: Tomczyk, Sara, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_s9kl0uk4q7ra66i433k7hcr1ht